Axim Biotechnologies Stock Price To Sales
| AXIM Stock | USD 0 0 33.33% |
Axim Biotechnologies fundamentals help investors to digest information that contributes to Axim Biotechnologies' financial success or failures. It also enables traders to predict the movement of Axim Pink Sheet. The fundamental analysis module provides a way to measure Axim Biotechnologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Axim Biotechnologies pink sheet.
Axim |
Axim Biotechnologies Company Price To Sales Analysis
Axim Biotechnologies' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Axim Biotechnologies Price To Sales | 943.93 X |
Most of Axim Biotechnologies' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Axim Biotechnologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Axim Biotechnologies has a Price To Sales of 943 times. This is much higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The price to sales for all United States stocks is notably lower than that of the firm.
Axim Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Axim Biotechnologies' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Axim Biotechnologies could also be used in its relative valuation, which is a method of valuing Axim Biotechnologies by comparing valuation metrics of similar companies.Axim Biotechnologies is currently under evaluation in price to sales category among its peers.
Axim Fundamentals
| Return On Equity | -100.19 | |||
| Return On Asset | -0.35 | |||
| Operating Margin | (847.86) % | |||
| Current Valuation | 13.6 M | |||
| Shares Outstanding | 186.44 M | |||
| Shares Owned By Insiders | 40.97 % | |||
| Price To Earning | (53.71) X | |||
| Price To Book | 2.86 X | |||
| Price To Sales | 943.93 X | |||
| Revenue | 60.46 K | |||
| Gross Profit | 60.46 K | |||
| EBITDA | (13.42 M) | |||
| Net Income | (16.03 M) | |||
| Cash And Equivalents | 65.16 K | |||
| Total Debt | 5.06 M | |||
| Debt To Equity | 1.36 % | |||
| Current Ratio | 0.06 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (2.49 M) | |||
| Earnings Per Share | (0.13) X | |||
| Beta | 1.49 | |||
| Market Capitalization | 4.64 M | |||
| Total Asset | 5.32 M | |||
| Retained Earnings | (36.37 M) | |||
| Working Capital | (1.36 M) | |||
| Current Asset | 1.18 M | |||
| Current Liabilities | 2.55 M | |||
| Z Score | -15.0 | |||
| Net Asset | 5.32 M |
About Axim Biotechnologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Axim Biotechnologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axim Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axim Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Axim Pink Sheet
Axim Biotechnologies financial ratios help investors to determine whether Axim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axim with respect to the benefits of owning Axim Biotechnologies security.